Cantor Fitzgerald Sticks to Its Buy Rating for Aldeyra Therapeutics

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Aldeyra Therapeutics (NASDAQ: ALDX) yesterday and set a price target of $23. The company’s shares closed yesterday at $8.45.

According to TipRanks.com, Piros is a 1-star analyst with an average return of -1.2% and a 52.7% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Strongbridge Biopharma Plc, and Global Blood Therapeutics.

Currently, the analyst consensus on Aldeyra Therapeutics is Moderate Buy and the average price target is $25, representing a 195.9% upside.

In a report released yesterday, Canaccord Genuity also maintained a Buy rating on the stock with a $27 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.90 and a one-year low of $3.90. Currently, Aldeyra Therapeutics has an average volume of 92.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Aldeyra Therapeutics, Inc. operates as a biotechnology company. It primarily focuses on the development of new products for immune-mediated, inflammatory, orphan and other diseases that are thought to be caused in part by naturally occurring toxic chemical species known as free aldehydes.